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Abstract. Portal vein invasion (PVI) is a major prognostic factor 
in hepatocellular carcinoma (HCC). The aim of the present 
study was to identify molecules that regulate PVI. Sections 
of cancerous tissue, paired noncancerous tissue and the PVI 
area were collected from 3 frozen HCC sections, using laser 
microdissection. The present study focused on 3 upregulated 
molecules, integrin β3 (ITGB3), secreted phosphoprotein 1 
(SPP1) and regulator of G-protein signaling 5 (RGS5), and 
2 molecules that were downregulated in PVI tissue compared 
with cancer tissue, metallothionein 1G (MT1G) and metallo-
thionein 1H (MT1H), as determined by cDNA microarray 
analysis. Reverse transcription-quantitative polymerase chain 
reaction analysis of 32 HCC cases revealed that RGS5 mRNA 
levels were significantly increased and MT1 G and MT1H 
mRNA levels were significantly decreased in cancerous tissue 
compared with noncancerous tissue. However, there was no 
significant difference in ITGB3 and SPP1 expression. There 
were no significant differences between the expression of 
these molecules and any clinicopathologic factors, including 
PVI. Immunohistochemical staining for RGS5 in 60 HCC 
cases demonstrated that RGS5 protein levels were higher in 
cancerous tissue compared with paired noncancerous tissue 
in 63.3% of HCC cases. Furthermore, high expression of 
RGS5 in cancerous tissue was significantly associated with 
PVI and tended to be associated with intrahepatic metastasis. 
Confluent multinodular type was significantly more frequent 
in cases with high expression of RGS5 in the cancerous tissue. 
Therefore, RGS5 may be a useful prognostic biomarker as well 
as a potential target of molecular therapy to treat HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common 
cancers globally. High-risk screening and early detection have 
improved the prognosis of patients with HCC. However, the 
prognosis of advanced HCC remains poor despite the intro-
duction of molecular targeted therapies. Portal vein invasion 
(PVI) is a major prognostic factor and is associated with 
intrahepatic metastasis and recurrence following curative 
resection. Des-γ‑carboxyprothrombin (DCP) levels and/or 
macroscopic findings, including simple nodular type tumors 
with extranodular growth and confluent multinodular type 
tumors, have been reported to be associated with PVI (1-4). 
Several molecules, including ubiquitin-conjugating enzyme 
E2C (5), importin-α1 (6), lysosomal-associated transmem-
brane protein 4β-35 (7), protein tyrosine phosphatase type 
IVA3 (8) and caveolin-1 (9), are reported to be associated with 
PVI. However, the precise mechanisms involved in the regula-
tion of PVI remain to be elucidated. Therefore, identification 
of the molecules regulating PVI is expected to contribute to 
the development of new molecular targeting therapies.
In the present study, molecules regulating PVI were probed 
using laser microdissection (LMD) and cDNA microarray 
analysis, and the role of these molecules in human HCC 
samples was evaluated.
Materials and methods
Ethics statement. The present study was approved by the Ethics 
Committee of Kurume University (Kurume, Japan; approval 
no. 13029). Written informed consent was obtained for cases 
from 2013. The Ethics Committee waived the requirement for 
written informed consent for cases from 2000 to 2004 as the 
data for these patients were retrospectively analyzed.
LMD. Frozen sections were obtained from 3 patients with 
HCC and PVI. All patients underwent curative hepatectomies 
for HCC at Kurume University Hospital (Kurume, Japan) 
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from January 2013 to March 2013. All patients were male; the 
patients were 59, 68 and 76 years old. No treatment prior to 
surgery had been conducted in all patients.
Cancerous tissue with the PVI and paired noncancerous 
tissue was immediately cut from the surgically resected 
livers and embedded in Tissue Tek O.C.T. compound (Sakura 
Finetek USA, Inc., Torrance, CA, USA). These samples were 
kept at ‑80˚C until use in the following procedure.
Sections (16 µm) were cut from the frozen tissue and the 
sections were stained with 0.05% toluidine blue. Each area 
(cancerous, paired noncancerous and PVI area) was micro-
dissected using an LMD system (Leica LMD6000, Leica 
Microsystems GmbH, Wetzlar, Germany; Fig. 1).
Gene expression microarrays. Total RNA in each of the 3 
areas was extracted using an RNAqueous‑Micro kit (Ambion; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) according 
to the manufacturer's protocol. The cRNA was amplified and 
labeled using a Low Input Quick Amp Labeling kit (Agilent 
Technologies, Inc., Santa Clara, CA, USA), and hybridized to 
a 60K Agilent 60-mer oligomicroarray (SurePrint G3 Human 
Gene Expression Microarray 8x60 K v2; Agilent Technologies, 
Inc., Santa Clara, CA, USA) according to the manufacturer's 
protocol. All hybridized microarray slides were scanned using 
an Agilent scanner (Agilent Technologies, Inc.). Relative 
hybridization intensities and background hybridization values 
were calculated using Agilent Feature Extraction software 
(9.5.1.1; Agilent Technologies, Inc.).
Data analysis and filter criteria. Raw signal intensities and 
flags for each probe were calculated from hybridization inten-
sities (gProcessedSignal) and spot information (gIsSaturated, 
etc.), according to the procedures recommended by Agilent 
Technologies, Inc. The flag criteria on GeneSpring software, 
version 12 (Agilent Technologies, Inc.) was as follows: Absent 
(A), feature is not positive, significant or above background; 
marginal (M), feature is not uniform, is saturated, and is a 
population outlier; present (P), others. The raw signal inten-
sities of two samples were log2-transformed and normalized 
by quantile algorithm with the ‘preprocessCore’ library 
package (10) on Bioconductor software, version 2.12 (11).
Probes with the ‘P’ flag were selected from the two 
samples. To identify up or downregulated genes, Z-scores (12) 
and ratios (non-log scaled fold-change) were calculated from 
the normalized signal intensities of each probe, for comparison 
between control and experimental samples. Then, criteria for 
regulated genes was established as follows: Upregulated genes 
were genes with a Z‑score ≥2.0 and ratio ≥1.5‑fold, while 
downregulated genes had a Z‑score ≤‑2.0 and ratio ≤0.66. A 
heat map was generated using MeV software, version 4.7.2 (13).
Reverse transcription‑quantitative polymerase chain 
reaction (RT‑qPCR). Frozen cancerous tissue and paired 
noncancerous tissue samples were obtained from 32 cases 
of HCC. All patients underwent curative hepatectomies for 
HCC at Kurume University Hospital (Kurume, Japan) from 
January 2000 to December 2003. No patients received preop-
erative anticancer therapies, including transcatheter arterial 
embolization or radiofrequency ablation. Patients with recur-
rent HCC and multiple HCC nodules were excluded.
Total RNA from cancerous tissue and paired noncancerous 
tissue was extracted using TRIzol reagent (Invitrogen; Thermo 
Fisher Scientific, Inc.), and complementary DNA (cDNA) 
was synthesized using the Reverse Transcription System 
(Promega, Madison, WI, USA), according to the manufac-
turers' protocols. RT-qPCR was performed using a 7500 
Real Time PCR System and TaqMan PCR Gene Expression 
Master Mix with Taqman PCR assay probe/primers for 
integrin β3 (ITGB3; Hs01001469_m1), secreted phospho-
protein 1 (SPP1; Hs00959010_m1), regulator of G-protein 
signaling 5 (RGS5; Hs01591223_s1), metallothionein 1 G 
(MT1G; Hs02578922_gH) and metallothionein 1H (MT1H; 
Hs00823168_g1); β-actin (Hs99999903-m1) was used as an 
internal control gene (all from Applied Biosystems; Thermo 
Fisher Scientific, Inc.). Thermocycler conditions were as 
follows: An initial incubation at 50˚C for 2 min, then 95˚C 
for 10 min, and then 45 cycles of 95˚C for 15 sec, 60˚C for 
1 min. To compare the mRNA expression levels in cancerous 
and noncancerous tissue, and thus the relationships between 
mRNA expression levels and clinicopathological factors, 
relative gene expression levels normalized by β-actin were 
calculated using the 2-ΔΔCq method (14).
Morphological observations. Formalin‑fixed, paraffin 
embedded (FFPE) 4‑µm sections were deparaffinized with 
xylene and soaked in hematoxylin for 5 min, followed by eosin 
for 5 min, at room temperature. Morphological observations 
were conducted on these FFPE sections under a light micro-
scope (low magnification x40 to high magnification x400; 
BX41; Olympus Corporation, Tokyo, Japan).
Immunohistochemistry. To further validate the expression 
of the candidate genes identified by cDNA microarrays at 
the protein level and their relationships with clinicopatho-
logic factors, immunohistochemical staining was performed 
on 4-µm FFPE tissue sections from 60 cases of HCC, 
containing cancerous and noncancerous tissues, that were 
surgically resected at Kurume University Hospital (Kurume, 
Japan) between January 2000 and December 2004. Of these 
60 cases, 29 were additionally used in the RT-qPCR analysis. 
No patients received preoperative anticancer therapies, 
including transcatheter arterial embolization or radiofre-
quency ablation, prior to surgical resection. Patients with 
recurrent HCC and multiple HCC nodules were excluded. 
Clinicopathological features of the 60 patients with HCC 
are summarized in Table I. Sections (4 µm) were cut from 
the FFPE liver samples that contained cancerous tissue and 
paired noncancerous tissue.
For RGS5, the sections were deparaffinized and rehy-
drated with xylene and 100% graded ethanol, respectively. 
The sections were subsequently soaked in Target Retrieval 
Solution, pH 9 (Dako; Agilent Technologies, Inc.) and treated 
at 95˚C in a pressure cooker for 40 min. Immunohistochemical 
staining was performed using a CSA II system (Dako; Agilent 
Technologies, Inc.) according to the manufacturer's protocol, 
with minor modification. The modifications were as follows: 
Endogenous peroxidase activity was quenched by incubation 
in H2O2 for 30 min. Nonspecific binding sites were blocked 
using a blocking solution for endogenous peroxidase (Dako; 
Agilent Technologies, Inc.) for 30 min, then tissue sections were 
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incubated with the primary antibody for 15-60 min at room 
temperature. The primary antibody used was a mouse mono-
clonal anti-human RGS5 (clone, 1C1; cat no. NBP2-00880; 
dilution, 1:250; Novus Biologicals, LLC, Littleton, CO, USA).
The results of the staining were evaluated independently, 
according to the staining intensity and the percentage of posi-
tive cells, by two pathologists, using the previously described 
light microscope. Initially, the whole slide was observed at x40 
magnification in order to assess the percentage of stained area. 
The staining intensity was then assessed at x200 magnification. 
The number of fields of view assessed depended on the stained 
area percentage. The staining intensity of the cancerous and 
PVI areas was scored on a scale from 0 to 3 compared with 
the noncancerous area, as follows: 0, when the intensity in the 
cancerous area was equal to that of the noncancerous area; 1, 
when the intensity in the cancerous area was slightly higher 
than that in the noncancerous area; 2, moderately higher and 3, 
markedly higher. The total expression score in the cancerous 
area was calculated by multiplying the staining intensity score 
by the percentage of stained area.
Statistical analysis. The Mann-Whitney U-test was used to 
examine the expression levels of ITGB3, SPP1, RGS5, MT1G 
and MT1H between noncancerous tissues and cancerous 
tissues, and to examine the association between expression 
levels of these molecules and clinicopathological factors. 
Associations among RGS5 expression, serum DCP levels, 
serum α-fetoprotein (AFP) levels (as evaluated during routine 
practice, prior to the present study) and tumor size were exam-
ined by calculating Spearman's rank correlation coefficients. 
Associations between RGS5 expression levels, serum DCP 
levels and serum AFP levels with clinicopathological factors 
were examined using Mann‑Whitney U‑tests. Logistic regres-
sion was used to determine whether RGS5 expression, serum 
DCP levels and serum AFP levels were associated with 
intrahepatic metastasis (IM) or PVI, adjusting for other clini-
copathological factors including age, sex, histological grade 
and gross type. Furthermore, logistic regression was used to 
examine whether RGS5 expression, serum DCP levels and 
serum AFP levels were associated with gross type, adjusting 
for other clinicopathological factors. P<0.05 was considered to 
indicate a statistically significant difference.
Results
cDNA microarray analysis. Upregulated or downregulated 
molecules in PVI tissue compared with cancerous tissue were 
detected by cDNA microarray analysis (Fig. 2). Only ITGB3 
was upregulated in all 3 HCC cases that were examined. On 
the other hand, MT1G and MT1H were downregulated in all 
3 cases. Of the upregulated molecules in 2 cases with high 
Z-scores, SPP1 and RGS5 were selected. Integrins are a family 
of transmembrane receptors and SPP1 is a ligand of integrin 
αVβ3, which is a combination of integrin subunit αV and β3. 
RGS5 has been reported to be a marker of cancer-associated 
endothelial cells (15) and is an endothelial cell marker that is 
highly expressed in HCC (16). Therefore, ITGB3, SPP1, RGS5, 
MT1 G and MT1H were focused on by the present study.
Table I. Clinicopathological factors of the 60 cases of hepato-
cellular carcinoma.
Clinicopathological factor Value 
Age (years; mean ± SD) 66.3±10.2
Sex (male/female) 52/8
Serum AFP levels (ng/ml; mean ± SD) 1733.4±5872.1
Serum DCP levels (mAU/ml; mean ± SD) 3377.7±12947.7
Gross type, n (%) 
  SN  39 (65.0)
  SNEG  13 (21.7)
  CM  7 (11.7)
  SNIM  1 (1.7)
Tumor size (mm; mean ± SD) 36.0±21.9
Histological grade, n (%) 
  Well-differentiated 2 (3.3)
  Moderately-differentiated 51 (85.0)
  Poorly-differentiated 7 (11.7)
Capsule formation, n (%) 45 (75.0)
Capsule invasion, n (%) 43 (71.7)
Portal vein invasion, n (%) 24 (40.0)
Intrahepatic metastasis n (%) 9 (15.0) 
SD, standard deviation; AFP, α-fetoprotein; DCP, 
des-γ‑carboxyprothrombin; SN, simple nodular type; SNEG, simple 
nodular type with extranodular growth; CM, confluent multinodular 
type; SNIM, small nodular type with indistinct margin.
Figure 1. (A) Representative panoramic view of frozen tissue obtained from 
hepatocellular carcinoma with portal vein invasion, stained with hematoxylin 
and eosin. The areas indicated by rectangles 1, 2 and 3 correspond to (B), 
before and after laser microdissection, stained by toluidine blue.
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RT‑qPCR analysis. RGS5 was significantly overexpressed at 
the mRNA level in cancerous tissue compared with noncan-
cerous tissue (P=0.0196; Fig. 3). However, there was no 
significant difference in ITGB3 and SPP1 mRNA expression 
(P=0.1265 and P=0.1165, respectively; Fig. 3). MT1G and 
MT1H mRNA expression levels were significantly lower in 
cancerous tissue compared with noncancerous tissue (P<0.01; 
Fig. 3). There were no significant associations between the 
expression of these molecules and any clinicopathological 
factors, including PVI.
RGS5 expression in HCC and clinicopathological factors. 
Immunohistochemical staining demonstrated that RGS5 
protein expression was higher in cancerous tissue compared 
Figure 3. Comparison of ITGB3, SPP1, RGS5, MT1G and MT1H gene expression levels between N and C tissue. Capped bars represent the 10 and 90th percen-
tiles. *P<0.05 and **P<0.01 vs. N. ITGB3, integrin β3; SPP1, secreted phosphoprotein 1; RGS5, regulator of G-protein signaling 5; MT1 G, metallothionein 1G; 
MT1H, metallothionein 1H; N, noncancerous; C, cancerous.
Figure 2. Heat map of the differentially expressed genes. A hierarchical clustering method was used to sort the genes. The color indicates the distance from the 
median of each row. The distance metric was the Pearson correlation, and the linkage method was average linkage clustering.
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with paired noncancerous tissue in 38/60 (63.3%) of HCC 
cases. RGS5 expression was observed in the cytoplasm. 
The average RGS5 expression score in cancerous tissue was 
0.58±0.68. RGS5 expression was significantly associated with 
PVI (P=0.0025; Table II) and tended to be associated with IM 
(P=0.1019; Table II). Out of RGS5 expression, serum DCP 
levels and serum AFP levels, only RGS5 was significantly 
associated with gross type (P=0.0068; Table II): RGS5 was 
higher in the confluent multinodular type. Spearman's rank 
correlation coefficients for RGS5 expression, serum DCP 
levels, serum AFP levels and tumor size revealed that RGS5 
expression and serum AFP levels were significantly associated 
with each other (r=0.387; P=0.0027), RGS5 expression was 
not associated with serum DCP levels or tumor size. On the 
other hand, serum DCP levels were significantly associated 
with tumor size (r=0.596; P<0.0001).
The results of the logistic regression analyses for PVI and 
IM were summarized in Tables III and IV, respectively. In these 
analyses, patients with well-differentiated type or small nodular 
type with an indistinct margin were excluded, since only a few 
Table II. Summary of RGS5 expression by portal vein invasion, intrahepatic metastasis and clinicopathological factors.
Clinicopathological factor  n min q1 median q3 max P‑value
Sex       0.4891
  Female 8 0.1 0.15 0.4 0.75 1.3 
  Male 52 0 0 0.2 1.15 2.4 
Gross type       0.0068
  SN 39 0 0 0.1 0.5 1.9 
  SNEG 13 0.1 0.5 1 1.3 2.1 
  CM 7 0 0 0.6 2.3 2.4 
  SNIM 1 0 0 0 0 0 
Histological grade       0.0313
  Well 2 0 0 0.1 0.2 0.2 
  Moderate 51 0 0 0.2 1.1 2.4 
  Poor 7 0.3 0.4 0.6 1.8 2.1 
Portal vein invasion       0.0025
  - 36 0 0 0.05 0.5 1.6 
  + 24 0 0.15 0.8 1.45 2.4 
Intrahepatic metastasis       0.1019
  - 51 0 0 0.2 1 2.4 
  + 9 0 0.5 0.8 1.4 1.9 
In testing for gross type and histological grade, subjects classified as SNIM and Well, respectively, were removed. RGS5, regulator of G‑protein 
signaling 5; SN, simple nodular type; SNEG, simple nodular type with extranodular growth; CM, confluent multinodular type; SNIM, small 
nodular type with indistinct margin; Well, well-differentiated hepatocellular carcinoma; Moderate, moderately-differentiated hepatocellular 
carcinoma; Poor, poorly-differentiated hepatocellular carcinoma.
Table III. Logistic regression for portal vein invasion.
Clinicopathological feature Unit OR (95% CI) P-value
Age 10 1.209 (0.6-2.436) 0.5949
Sex Female/Male 2.703 (0.379‑19.288) 0.3212
Histological grade Mode/Poor 0.264 (0.016‑4.487) 0.3569
Gross type SNEG, CM/SN 12.059 (2.664‑54.586) 0.0012
RGS5 1 2.359 (0.74-7.517) 0.1466
AFP 480 1.071 (0.957-1.197) 0.2324
DCP 500 0.968 (0.916-1.024) 0.2576
RGS5 expression, serum AFP levels and serum DCP levels were treated as continuous variables and units for the OR were determined referring 
to the difference between the upper and lower 25% percentiles. OR, odds ratio; CI, confidence interval; RGS5, regulator of G‑protein signaling 5; 
AFP, α-fetoprotein; DCP, des-γ‑carboxyprothrombin; Mode, moderately‑differentiated hepatocellular carcinoma; Poor, poorly‑differentiated 
hepatocellular carcinoma; SNEG, simple nodular type with extranodular growth; CM, confluent multinodular type; SN, simple nodular type.
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patients were classified into these categories. Gross type was 
associated with PVI (P=0.0012; Table III), whereas RGS5 
expression, serum DCP levels and serum AFP levels were not 
associated with PVI. No clear association was observed between 
IM and gross type (P=0.0698; Table IV). Logistic regression 
analysis for associations between gross type and other factors 
revealed that RGS5 expression was significantly associated with 
gross type (P=0.0145; Table V), but not with serum DCP levels 
or serum AFP levels, upon adjusting for other clinicopatho-
logical factors. In addition, in 16/24 (66.7%) cases of HCC with 
PVI, the staining intensity within the PVI area was equal to or 
stronger than that of cancerous tissue (Fig. 4).
Discussion
In the present study, noncancerous, cancerous and PVI areas 
were selected using the LMD method, and a comprehensive 
analysis of these samples was conducted using cDNA micro-
array techniques. Among the extracted molecules, RGS5 was 
demonstrated to potentially regulate PVI in HCC.
RGS5 is a member of the RGS protein family and RGS 
proteins act as GTPase-activating proteins for heterotorimeric 
G protein α subunits, negatively regulating G-protein 
signaling (17-19). RGS5 was reported to be expressed in the 
heart, lung, skeletal muscle and small intestine (20). It is also 
reported to be expressed in pericytes and vascular smooth 
muscle cells (21). With regard to RGS5 and cancer, RGS5 
expression has been demonstrated to be positively correlated 
with the degree of tumor differentiation in gastric carci-
noma (22).
The results of the present study support those of 
Hu et al (23) who also used RT-qPCR to analyze tissue from 
20 patients with HCC and revealed that RGS5 expression was 
higher in cancerous tissue compared with noncancerous tissue, 
and that RGS5 expression was higher in liver cancer cell lines 
than in matched normal tissue. They also reported that recur-
rence and venous infiltration were more frequent and that 
disease‑free survival was lower in 40 cases of HCC that overex-
pressed RGS5, as determined by RT-qPCR. The present study 
observed no significant difference in RGS5 expression at the 
mRNA level (P=0.1844), but immunohistochemical staining 
revealed that high RGS5 expression in cancer tissue was 
significantly correlated with PVI. There was also a tendency 
towards increased IM in cases with high RGS5 expression, 
Table V. Logistic regression for gross type.
Clinicopathological feature Unit OR (95% CI) P-value
Age 10 1.175 (0.654-2.111) 0.5905
Sex Female/Male 0.74 (0.091‑6.035) 0.7786
Histological grade Mode/Poor 0.654 (0.065‑6.585) 0.7184
RGS5 1 3.628 (1.291-10.196) 0.0145
AFP 480 0.928 (0.788-1.093) 0.371
DCP 500 1.036 (0.968-1.108) 0.3079
RGS5 expression, serum AFP levels and serum DCP levels were treated as continuous variables and units for the OR were determined referring 
difference between upper and lower 25 percent percentiles. OR, odds ratio; CI, confidence interval; RGS5, regulator of G‑protein signaling 5; 
AFP, α-fetoprotein; DCP, des-γ‑carboxyprothrombin; Mode, moderately‑differentiated hepatocellular carcinoma; Poor, poorly‑differentiated 
hepatocellular carcinoma.
Table IV. Logistic regression for intrahepatic metastasis.
Clinicopathological feature Unit OR (95% CI) P-value
Age 10 1.274 (0.513-3.168) 0.6021
Sex Female/Male 0.468 (0.028‑7.911) 0.5984
Histological grade Mode/Poor 1.048 (0.073‑15.127) 0.9726
Gross type SNEG, CM/SN 4.57 (0.884‑23.629) 0.0698
RGS5 1 1.517 (0.439-5.235) 0.5098
AFP 480 1.052 (0.952-1.162) 0.3184
DCP 500 0.991 (0.945-1.039) 0.7012
RGS5 expression, serum AFP levels and serum DCP levels were treated as continuous variables and units for the OR were determined 
referring to the difference between the upper and lower 25% percentiles. Firth's correction was employed to stabilize estimates. OR, odds 
ratio; CI, confidence interval; RGS5, regulator of G‑protein signaling 5; AFP, α-fetoprotein; DCP, des-γ‑carboxyprothrombin; Mode, 
moderately-differentiated hepatocellular carcinoma; Poor, poorly-differentiated hepatocellular carcinoma; SNEG, simple nodular type with 
extranodular growth; CM, confluent multinodular type; SN, simple nodular type.
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although the difference was not statistically significant. One 
potential reason RGS5 expression was not significantly associ-
ated with PVI at the mRNA level may be that the number of 
cases examined by RT‑qPCR was too small, consisting of only 
29 of the 60 cases subjected to immunostaining. Furthermore, 
with regard to gross type, cases where immunostaining 
revealed high expression of RGS5 were significantly more 
likely to be confluent multinodular type HCC. The logistic 
regression analyses revealed that RGS5 expression was not an 
independent prognostic factor for PVI, whereas the gross type 
was. RGS5 was revealed to be associated with the gross type 
independently of other clinicopathological factors, indicating 
that RGS5 is involved in the determination of the gross type 
and thus may contribute to PVI. In HCC, gross classification as 
confluent multinodular type or nodular type with extranodular 
growth has frequently been associated with PVI (2-4), and 
these previous reports support the results of the present study; 
that RGS5 is associated with PVI.
Furuya et al (24) examined the localization of RGS5 
by using in situ hybridization (ISH) in the kidney, and 
observed strong expression of RGS5 in vessels within tumor 
cell nests, but not in tumor cells or in endothelial cells of 
normal kidney vasculature. Immunohistochemical staining 
suggested that the primary location of RGS5 was tumor 
endothelial cells. Silini et al (15) reported higher levels of 
RGS5 mRNA in endothelial cells isolated from carcinomas, 
primarily ovarian carcinomas, compared with endothelial 
cells isolated from non-neoplastic tissue. In a study of 
hepatic tissue, Chen et al (16) used ISH to demonstrate that 
RGS5 was not expressed in sinusoidal endothelial cells in 
non-tumor liver tissues, detected RGS5 mRNA in the sinu-
soidal endothelial cells in the HCC samples. The present 
study used immunohistochemical staining to reveal that 
RGS5 was expressed in the cytoplasm of HCC cells. Staining 
was not clearly observed in sinusoidal endothelial cells 
in the noncancerous and cancerous areas. Wang et al (22) 
performed immunohistochemical staining of RGS5 in 
gastric carcinoma and revealed that RGS5 was expressed in 
the cytoplasm of cancer cells. Huang et al (25) also reported 
RGS5 expression in the cytoplasm and the cell membrane 
of non-small cell lung cancer cells, using immunostaining. 
Furthermore, unpublished data from this laboratory used 
western blotting to observe RGS5 expression in an HCC 
cell line (data not shown), a result that supported the immu-
nohistochemical staining results, which revealed RGS5 
expression in HCC cells.
Furthermore, in 66.7% of the HCC cases with PVI, immu-
nohistochemical staining intensity was as strong or stronger in 
the PVI tissue as in the cancerous tissue. Hu et al (23) reported 
that knockdown of RGS5 suppressed cell migration and inva-
sion, suggesting that cancer cells with high RGS5 expression 
have increased invasive activity, including PVI.
In conclusion, RGS5 expression in cancerous tissues was 
significantly upregulated at the mRNA and protein levels 
compared with noncancerous tissue, and was significantly 
associated with PVI in HCC. RGS5 may therefore be a useful 
prognostic biomarker as well as a potential target for molecular 
therapy for the treatment of HCC.
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